#United States #New York #Clinical Trials #TransPerfect #GlobalLink

TransPerfect's GlobalLink Technology Brings $2.55M Savings

In a groundbreaking report released by Forrester Consulting, TransPerfect Life Sciences has demonstrated the substantial financial benefits of its GlobalLink technology suite, revealing a staggering $2.55 million in savings for a global pharmaceutical company. This independent study, commissioned by TransPerfect but conducted without bias by Forrester, showcases how their integrated technology has transformed clinical trial efficiencies.

TransPerfect stands as a leading provider of content solutions tailored for the biopharmaceutical sector, facilitating smooth global clinical trials and product development. The findings of this study underscore the critical impact of adopting standardized translation tools and processes, a shift from the disjointed and decentralized operations that plagued many organizations in the field.

The Challenge of Inefficiency

Before embracing the GlobalLink technology, the pharmaceutical company struggled with fragmented translation workflows. With multiple local affiliates independently selecting translation providers, there was a lack of consistency and control in quality. This decentralization led to inefficiencies, compromised regulatory compliance, and inflated operational costs. The organization faced challenges such as reduced visibility into supplier performance, poor content quality, and an overburdened internal team, all stemming from outdated methods of managing multilingual content.

The procurement category lead from the organization highlighted the confusion of managing such an uncoordinated setup: "It made sense that you would try to streamline and standardize from my perspective in procurement. I think our biggest benefit here was getting more transparency and a better level of oversight.”

Integrating Advanced Technology

By integrating GlobalLink's AI-powered translation solutions with their existing content management systems and clinical document management systems, this pharmaceutical giant was able to revamp their approach to translations. The transition fostered better governance practices, significantly cut costs, and ensured high-quality translations across various regions.

This technology enables centralized management of translation data, reducing the need for repetitive data entries or processes that previously contributed to delays. As a result, the organization can now mitigate risks effectively while also simplifying workflows, thus speeding up the timeline from lab to market.

Phil Shawe, President and Co-CEO of TransPerfect, commented on the findings: "Our life sciences clients rely on GlobalLink to generate cost- and time-efficiencies in managing multilingual content for their clinical and regulatory teams. We view this independent study as providing further validation that these efforts are succeeding." This endorsement from a respected leader in the industry underscores the continued reliability and necessity of GlobalLink solutions in the competitive biopharmaceutical landscape.

Why It Matters

The savings articulated in the study not only reflect financial relief for the organization but also signal a transformation in how clinical trials are conducted globally. With health and regulatory authorities increasingly emphasizing the importance of accurate multilingual documentation, having a unified translation strategy is not just preferable but essential.

TransPerfect Life Sciences boasts expertise in various aspects of clinical trial translation, drug development, and regulatory language services. Their approach is designed to support the critical objectives of pharmaceutical clients while significantly enhancing patient engagement. With a worldwide presence across over 140 cities, TransPerfect is the go-to partner for businesses aiming to ease the path from lab to launch.

In conclusion, the independent study reveals how technological advancements like TransPerfect's GlobalLink can fundamentally change the landscape of clinical trials. The move towards integrating AI-driven solutions not only fosters better efficiency and quality standards but ultimately serves to improve health outcomes through more effective global collaboration in the industry.